Oncocyte Corporation (OCX) Actualités

Form D - Notice of Exempt Offering of Securities

Form 4 - Statement of changes in beneficial ownership of securities

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Oncocyte Prices $29.1 Million Equity Offering

Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial LaunchStrategic Partner...

Form 8-K - Current report

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision...

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Medicare coverage expanded following study showing that monitoring with Oncocyte’s assay significantly reduces...

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

IRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics...

Form 4 - Statement of changes in beneficial ownership of securities

Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study

IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology...

Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms 

Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report